Search

Vivian C. Chin

Supervisory Patent Examiner (ID: 17044, Phone: (571)272-7848 , Office: P/2654 )

Most Active Art Unit
2747
Art Unit(s)
2654, 2644, 2695, 2605, 2747, 2608, 2743, 2615, 2614, 2609, 2682
Total Applications
608
Issued Applications
319
Pending Applications
136
Abandoned Applications
157

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 17734764 [patent_doc_number] => 20220220223 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-14 [patent_title] => TREATMENT OF ALLERGIC DISEASES WITH CHIMERIC PROTEIN [patent_app_type] => utility [patent_app_number] => 17/711517 [patent_app_country] => US [patent_app_date] => 2022-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19747 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17711517 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/711517
Treatment of allergic diseases with chimeric protein Mar 31, 2022 Issued
Array ( [id] => 19202855 [patent_doc_number] => 20240174754 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-30 [patent_title] => ANTI-KLRG1 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/552515 [patent_app_country] => US [patent_app_date] => 2022-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15905 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18552515 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/552515
ANTI-KLRG1 ANTIBODIES Mar 24, 2022 Pending
Array ( [id] => 19521138 [patent_doc_number] => 12122847 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-22 [patent_title] => Factor VII (FVII(a))/TREM-like transcript 1 (TLT-1) bispecific antibodies [patent_app_type] => utility [patent_app_number] => 17/699460 [patent_app_country] => US [patent_app_date] => 2022-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31264 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 263 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17699460 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/699460
Factor VII (FVII(a))/TREM-like transcript 1 (TLT-1) bispecific antibodies Mar 20, 2022 Issued
Array ( [id] => 17851916 [patent_doc_number] => 20220281958 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-08 [patent_title] => HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) [patent_app_type] => utility [patent_app_number] => 17/655503 [patent_app_country] => US [patent_app_date] => 2022-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 60524 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17655503 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/655503
Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Mar 17, 2022 Issued
Array ( [id] => 20129443 [patent_doc_number] => 12371747 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-29 [patent_title] => Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy [patent_app_type] => utility [patent_app_number] => 17/681435 [patent_app_country] => US [patent_app_date] => 2022-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 50 [patent_figures_cnt] => 114 [patent_no_of_words] => 53313 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 139 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17681435 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/681435
Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy Feb 24, 2022 Issued
Array ( [id] => 17792066 [patent_doc_number] => 20220251157 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-11 [patent_title] => IgM-MEDIATED RECEPTOR CLUSTERING AND CELL MODULATION [patent_app_type] => utility [patent_app_number] => 17/674438 [patent_app_country] => US [patent_app_date] => 2022-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16196 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17674438 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/674438
IgM-MEDIATED RECEPTOR CLUSTERING AND CELL MODULATION Feb 16, 2022 Abandoned
Array ( [id] => 17828476 [patent_doc_number] => 20220265780 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => FACTOR VIII-FC CHIMERIC AND HYBRID POLYPEPTIDES, AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/587941 [patent_app_country] => US [patent_app_date] => 2022-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24769 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17587941 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/587941
FACTOR VIII-FC CHIMERIC AND HYBRID POLYPEPTIDES, AND METHODS OF USE THEREOF Jan 27, 2022 Pending
Array ( [id] => 17749667 [patent_doc_number] => 20220227871 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-21 [patent_title] => ANTI-PD-L1 ANTIBODY [patent_app_type] => utility [patent_app_number] => 17/579517 [patent_app_country] => US [patent_app_date] => 2022-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19446 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17579517 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/579517
ANTI-PD-L1 ANTIBODY Jan 18, 2022 Abandoned
Array ( [id] => 17704639 [patent_doc_number] => 20220204645 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-30 [patent_title] => ANTIBODIES THAT RECOGNIZE RED BLOOD CELL ANTIGENS [patent_app_type] => utility [patent_app_number] => 17/571075 [patent_app_country] => US [patent_app_date] => 2022-01-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13776 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17571075 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/571075
Antibodies that recognize red blood cell antigens Jan 6, 2022 Issued
Array ( [id] => 19034202 [patent_doc_number] => 20240084017 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => MONOCLONAL ANTIBODY AGAINST HUMAN MAC-1 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/259958 [patent_app_country] => US [patent_app_date] => 2021-12-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6722 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18259958 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/259958
MONOCLONAL ANTIBODY AGAINST HUMAN MAC-1 AND USES THEREOF Dec 29, 2021 Pending
Array ( [id] => 17761534 [patent_doc_number] => 20220235146 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-28 [patent_title] => ANTI-IgE ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/541932 [patent_app_country] => US [patent_app_date] => 2021-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41212 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17541932 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/541932
Anti-IgE antibodies Dec 2, 2021 Issued
Array ( [id] => 17460339 [patent_doc_number] => 20220073644 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-10 [patent_title] => BISPECIFIC ANTIBODY EXHIBITING INCREASED ALTERNATIVE FVIII-COFACTOR-FUNCTION ACTIVITY [patent_app_type] => utility [patent_app_number] => 17/528371 [patent_app_country] => US [patent_app_date] => 2021-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24918 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 116 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17528371 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/528371
Bispecific antibody exhibiting increased alternative FVIII-cofactor-function activity Nov 16, 2021 Issued
Array ( [id] => 18212457 [patent_doc_number] => 20230058721 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-23 [patent_title] => Procoagulant Antibodies [patent_app_type] => utility [patent_app_number] => 17/522949 [patent_app_country] => US [patent_app_date] => 2021-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56494 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17522949 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/522949
Procoagulant Antibodies Nov 9, 2021 Abandoned
Array ( [id] => 18901447 [patent_doc_number] => 20240016932 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-18 [patent_title] => CHIMERIC ANTIGEN RECEPTOR [patent_app_type] => utility [patent_app_number] => 18/034999 [patent_app_country] => US [patent_app_date] => 2021-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9426 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18034999 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/034999
CHIMERIC ANTIGEN RECEPTOR Nov 8, 2021 Pending
Array ( [id] => 17837752 [patent_doc_number] => 20220275057 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-01 [patent_title] => FACTOR VIII CHIMERIC PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/519719 [patent_app_country] => US [patent_app_date] => 2021-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57344 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17519719 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/519719
FACTOR VIII CHIMERIC PROTEINS AND USES THEREOF Nov 4, 2021 Pending
Array ( [id] => 18893818 [patent_doc_number] => 20240009303 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-11 [patent_title] => COMBINATION VACCINE FOR PROTECTING SWINE AGAINST VARIOUS DISORDERS [patent_app_type] => utility [patent_app_number] => 18/250106 [patent_app_country] => US [patent_app_date] => 2021-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6388 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18250106 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/250106
COMBINATION VACCINE FOR PROTECTING SWINE AGAINST VARIOUS DISORDERS Oct 27, 2021 Pending
Array ( [id] => 18895495 [patent_doc_number] => 20240010980 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-11 [patent_title] => NATURAL KILLER CELLS WITH ENHANCED ACTIVITY [patent_app_type] => utility [patent_app_number] => 18/249991 [patent_app_country] => US [patent_app_date] => 2021-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17454 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -54 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18249991 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/249991
NATURAL KILLER CELLS WITH ENHANCED ACTIVITY Oct 26, 2021 Pending
Array ( [id] => 17587727 [patent_doc_number] => 11325983 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-10 [patent_title] => Bispecific antibodies [patent_app_type] => utility [patent_app_number] => 17/501548 [patent_app_country] => US [patent_app_date] => 2021-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31201 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 148 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17501548 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/501548
Bispecific antibodies Oct 13, 2021 Issued
Array ( [id] => 17356842 [patent_doc_number] => 20220017638 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => METHOD OF TREATING ATHEROSCLEROSIS [patent_app_type] => utility [patent_app_number] => 17/498112 [patent_app_country] => US [patent_app_date] => 2021-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24361 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17498112 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/498112
METHOD OF TREATING ATHEROSCLEROSIS Oct 10, 2021 Abandoned
Array ( [id] => 17482274 [patent_doc_number] => 20220089778 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-24 [patent_title] => COAGULATION FACTOR BINDING PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/450423 [patent_app_country] => US [patent_app_date] => 2021-10-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33214 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17450423 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/450423
COAGULATION FACTOR BINDING PROTEINS AND USES THEREOF Oct 7, 2021 Abandoned
Menu